Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Introduction of Ivacaftor/Lumacaftor in Children With Cystic Fibrosis Homozygous for F508del in the Netherlands: A Nationwide Real-Life Study.
Pediatr Pulmonol
January 2025
Beatrix Children's Hospital Department of Pediatric Pulmonology and Pediatric Allergy, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Introduction: Lumacaftor/ivacaftor (lum/iva) was introduced in the Netherlands in 2017. We investigated 1-year efficacy of lum/iva on lung function and small airway and structural lung disease evaluated by multiple breath nitrogen washout and CT scan. Additionally, we investigated effects of lum/iva on exacerbations, anthropometry, sweat chloride and safety in children with CF in the Netherlands.
View Article and Find Full Text PDFObjective: To assess the prevalence of risk factors of cardiovascular disease (CV RF) development and awareness of them among young people studing at University.
Material And Methods: Сross-sectional study study included 1182 young men and women studying at Lomonosov Moscow State University (age 18-44 years), with no history of chronic non-infectious diseases, who underwent a screening in April-June 2022. All participants filled out the standard "Questionnaire for citizens under the age of 65 years to identify chronic non-communicable diseases, risk factors for their development, and the use of narcotic drugs and psychotropic substances without prescription", a specially designed questionnaire on socio-demographic characteristics and risk factors for CVD development, and a questionnaire on nighttime sleep status.
Background: NA-831 is a candidate for the treatment of Alzheimer's Disease (AD). NA-911 is an analog of NA-831, serving as an IGF-1 and GLP-1 agonists. Animal studies of NA-911 are evaluated for the treatment of by hypoxic-ischemic injury, hemorrhagic stroke, and chronic neurodegenerative disorders METHOD: For NA-831: A randomized clinical trial of NA-831 was performed in 112 participants with mild and moderate AD, half received the drugs and half received placebo.
View Article and Find Full Text PDFAntihypertensive strategies for the prevention of secondary stroke: a systematic review and meta-analysis.
Eur J Med Res
January 2025
West China School of Nursing, Sichuan University, Chengdu, 610041, Sichuan, China.
Background: Stroke is an important contributor to disability and death globally. Hypertension is a main risk factor for recurrent stroke in patients with ischemic and hemorrhagic stroke or transient ischemic attack. Higher systolic blood pressure, diastolic blood pressure, pulse pressure and mean arterial pressure at admission are independently associated with the risk of stroke recurrence.
View Article and Find Full Text PDFPostdiagnostic use of antihypertensive medications and survival in colorectal, lung, corpus uteri, melanoma and kidney cancer patients with hypertension.
BMC Cancer
January 2025
Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Background: Arterial hypertension is one of the most frequent comorbidities in patients with cancer. Studies have indicated that drugs used to control hypertension may alter cancer patient survival; however, epidemiological findings for their impact on cancer survival remain inconsistent. The aim of this study was to examine the effect of the consumption of antihypertensive (AH) medication on the risk of death in cancer patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!